News

Metabolic syndrome linked to increased risk for most endometrial cancer subtypes


 

FROM CANCER EPIDEMIOLOGY, BIOMARKERS, AND PREVENTION

References

Elderly women in the United States who have metabolic syndrome and its related factors face an increased risk of endometrial cancer, according to an analysis of Surveillance, Epidemiology and End Results (SEER)–Medicare data.

Researchers from the National Cancer Institute evaluated data from 16,323 women aged 65 years and older in the SEER database who were diagnosed with endometrial cancer from 1997 through 2007, as well as a sample of 100,751 Medicare enrollees (controls) who lived in the same SEER registry area as the cases. Endometrial cancer was found associated with metabolic syndrome (odds ratio, 1.39; 95% CI 1.32-1.47) and several component factors, reported Britton Trabert, Ph.D., and associates at the National Cancer Institute, Bethesda, Md.

Dr. Britton Trabert Courtesy AACR

Dr. Britton Trabert

Of the component factors of metabolic syndrome, being overweight conferred the greatest risk (OR, 1.95; 95% CI 1.80-2.11), followed by impaired fasting glucose (OR, 1.36; 95% CI 1.30-1.43), high blood pressure (OR, 1.31; 95% CI 1.25-1.36), and high triglycerides (OR, 1.13; 95% CI 1.08-1.18).

“Adjusting for overweight/obesity did not substantively attenuate risk estimates for the other metabolic component factors evaluated in the current study or in other study populations,” Dr. Trabert and her associates said (Canc. Epidem., Biomarkers and Prev. 2015 Jan. 13 [doi:10.1158/1055-9965.EPI-14-0923]).

The investigators also evaluated the associations with risk factors by subtype, including low grade (grade 1 and 2) endometrioid, high-grade (grade 3) endometrioid, adenocarcinoma, mucinous, serous, clear cell, carcinosarcoma, sarcoma, and “other” endometrial cancer subtypes. Metabolic syndrome was associated with increased risk for all endometrial cancer subtypes except for carcinosarcomas (OR, 1.14; 95% CI 0.94-1.38) and sarcomas (OR, 1.34; 95%CI 0.94-1.92).

“The results of this population-based study indicated that metabolic syndrome is a significant risk factor for endometrial cancer with consistent associations across endometrial cancer subtypes,” Dr. Trabert and her associates concluded.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Recommended Reading

Everolimus approval now includes prevention of liver transplant rejection
MDedge Hematology and Oncology
Lipid metabolism genes linked to breast cancer subtype
MDedge Hematology and Oncology
Study suggests statin use decreases breast cancer mortality
MDedge Hematology and Oncology
Varenicline helps smokers with stably treated depression
MDedge Hematology and Oncology
Surgeon General report links smoking to diseases beyond cancer
MDedge Hematology and Oncology
Statins may reduce prostate cancer deaths
MDedge Hematology and Oncology
Polyp, adenoma detection rises with Endocuff device
MDedge Hematology and Oncology
Drugs approved in 2013
MDedge Hematology and Oncology
FDA approves blood test for membranous glomerulonephritis
MDedge Hematology and Oncology
Liver cancer without cirrhosis surprisingly common: Is NAFLD the cause?
MDedge Hematology and Oncology